Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.

ABSTRACT: Radiation therapy is often combined with androgen deprivation therapy in the treatment of aggressive localized prostate cancer. However, castration-resistant disease may not respond to testosterone deprivation approaches. Enzalutamide is a second-generation anti-androgen with high affinity and activity that is used for the treatment of metastatic disease. Although radiosensitization mechanisms are known to be mediated through androgen receptor activity, this project aims to uncover the detailed DNA damage repair factors influenced by enzalutamide using multiple models of androgen-sensitive (LNCaP) and castration-resistant human prostate cancer (22Rv1 and DU145). Enzalutamide is able to radiosensitize both androgen-dependent and androgen-independent human prostate cancer models in cell cult

SUBMITTER: Sekhar KR 

PROVIDER: S-EPMC6443157 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature